Thus, we can assume that IFN-DC developing in vivo under pathological conditions or during IFN-α therapy can take-up apoptotic bodies from tumor cells and self cells as well, and can prime both Th1 and Th17 responses, thus leading to the expansion and activation of effectors T cells reactive against tumor-associated and self antigens. The gene discussed is IFNA2; the disease is neoplasm.